Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval.Beverly A. Teicher

1998 ◽  
Vol 73 (1) ◽  
pp. 123-124
Author(s):  
Edmund K. LeGrand
Keyword(s):  
Clinical Trials ◽  
Drug Development ◽  
Anticancer Drug ◽  
Preclinical Screening ◽  
Anticancer Drug Development

scholarly journals PROSPECTIVE AND RETROSPECTIVE ANIMAL MODEL USED IN THE PHARMACOLOGICAL SCREENING OF ANTI-CANCER DRUG

2018 ◽  
Vol 10 (4) ◽  
pp. 13
Author(s):  
Shamima Nasreen Ahmed ◽  
Biswajit Das ◽  
Jashabir Chakraborty
Keyword(s):  
Drug Development ◽  
Anticancer Drug ◽  
Drug Screening ◽  
Rapid Development ◽  
The Body ◽  
Cytotoxic Agents ◽  
Cancer Drug ◽  
Tumor Models ◽  
Preclinical Screening ◽  
Anticancer Drug Development

Cancer is a disease characterized by uncontrolled proliferation of cells that have transformed from the normal cells of the body. The widely used cancer drugs suffers from the drawback of high toxicity not within the reach of a common man. This urgently necessitating the screening of these compounds. This review focuses on the major contributions of preclinical screening models to anticancer drug development over the years till recent times, from the empirical drug screening of cytotoxic agents against uncharacterized tumor models to the target-orientated drug screening of agents with defined mechanisms of action,, a general transition has been observed. The newer approaches to anticancer drug development involve the molecular characterization of models along with an appreciation of the pharmacodynamics and pharmacokinetic properties of compounds [e. g., the US National Cancer Institute (NCI) in vitro 60-cell line panel, hollow fibre assay, and s. c. xenograft]. In vivo tumor models including orthotopic, metastatic, and genetically engineered mouse models are also reviewed. The preclinical screening efforts of the European are also included. In 2015 with the rapid development of cancer modeling in zebrafish, great opportunities exist for chemical screens to find anticancer drug since 1970 the European Organisation for Research and Treatment of Cancer and Cancer Research UK, have been collaborating with the NCI in the acquisition and screening of compounds.

Applications of liquid biopsy in the Pharmacological Audit Trail for anticancer drug development

2021 ◽  
Author(s):  
Abhijit Pal ◽  
Rajiv Shinde ◽  
Manuel Selvi Miralles ◽  
Paul Workman ◽  
Johann de Bono
Keyword(s):  
Drug Development ◽  
Anticancer Drug ◽  
Liquid Biopsy ◽  
Audit Trail ◽  
Anticancer Drug Development

Non-invasive MRS in new anticancer drug development

1992 ◽  
Vol 5 (5) ◽  
pp. 270-272 ◽  
Author(s):  
Paul Workman ◽  
Ross J. Maxwell ◽  
John R. Griffiths
Keyword(s):  
Drug Development ◽  
Anticancer Drug ◽  
Non Invasive ◽  
Anticancer Drug Development
Sign in / Sign up

Export Citation Format

Share Document